Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

    Authors: Lucas M Kimmig; David Wu; Matthew Gold; Natasha N Pettit; David Pitrak; Jeffrey Mueller; Aliya N Husain; Ece A Mutlu; Gokhan M Mutlu

    doi:10.1101/2020.05.15.20103531 Date: 2020-05-20 Source: medRxiv

    Background Anti-inflammatory therapies such as IL-6 inhibition have been proposed for COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory response in infectious diseases MESHD may impair a desired host response and predispose to secondary infections. Methods We retrospectively reviewed the medical record of critically ill COVID-19 patients during an 8-week span and compared the prevalence SERO of secondary infection MESHD and outcomes in patients who did and did not receive tocilizumab. Additionally, we included representative histopathologic post-mortem findings from several COVID-19 cases that underwent autopsy at our institution. Results 111 patients were identified, of which 48 had received tocilizumab while 63 had not. Receiving tocilizumab was associated with a higher risk of secondary bacterial (50% vs. 28.6%, p=0.021 and fungal (8.3% vs. 0%, p=0.078) infections. Consistent with higher number of infections, patients who received tocilizumab had higher mortality (39.6 vs. 17.4%, p=0.016). Seven cases underwent autopsy. In 3 cases who received tocilizumab, there was evidence of pneumonia HP on pathology. Of the 4 cases that had not been given tocilizumab, 2 showed evidence of aspiration pneumonia HP and 2 exhibited diffuse alveolar damage. Conclusions Experimental therapies are currently being applied to COVID-19 outside of clinical trials. Anti-inflammatory therapies such as anti-IL-6 therapy have the potential to impair viral clearance, predispose to secondary infection, and cause harm. We seek to raise physician awareness of these issues and highlight the need to better understand the immune response in COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.